Results 41 to 50 of about 162,270 (298)

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV

Frontiers in Immunology, 2023
The success of the first licensed mRNA-based vaccines against COVID-19 has created a widespread interest on mRNA technology for vaccinology. As expected, the number of mRNA vaccines in preclinical and clinical development increased exponentially since ...
Laura Matarazzo, Laura Matarazzo, Paulo J. G. Bettencourt, Paulo J. G. Bettencourt   +3 more
doaj   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy

Frontiers in Immunology, 2022
mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA ...
Zhuoya Deng, Yuying Tian, Jianxun Song, Guangwen An, Penghui Yang   +4 more
doaj   +1 more source

RNA interference approaches for treatment of HIV-1 infection. [PDF]

, 2015
HIV/AIDS is a chronic and debilitating disease that cannot be cured with current antiretroviral drugs. While combinatorial antiretroviral therapy (cART) can potently suppress HIV-1 replication and delay the onset of AIDS, viral mutagenesis often leads to
Bobbin, Maggie L, Burnett, John C, Rossi, John J   +2 more
core   +1 more source

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A., Pattison, Amanda M., Rappaport, Jeff A., Sato, Takami, Snook, Adam E., Waldman, Scott A.   +5 more
core   +2 more sources

Immunogenicity of targeted lentivectors [PDF]

, 2014
To increase the safety and possibly efficacy of HIV-1 derived lentivectors (LVs) as an anti-cancer vaccine, we recently developed the Nanobody (Nb) display technology to target LVs to antigen presenting cells (APCs).
Adotévi, Bennett, Bevan, Bhardwaj, Bhardwaj, Bhardwaj, Blander, Bonehill, Bonehill, Breckpot, Breckpot, Breckpot, Charleston, Chuah, Collins, Collins, Collins, Collins, Cosset, Diebold, Donckier, Eggermont, Enk, Figdor, Gajewski, Garcia, Groettrup, Inaba, Kast, Lahoutte, Lévy, McCullough, Medzhitov, Melief, Mellman, Mortha, Moser, Moser, Munn, Naldini, Neyns, Noguiez-Hellin, Nussenzweig, Palena, Raes, Reis e Sousa, Reiser, Reiser, Richardson, Romani, Roncarolo, Sakuma, Schroyens, Semesyuk, Song, Storm, Thielemans, Thielemans, Thielemans, Thielemans, Torretta, Turk, Van Kooyk, Wang, Wang, Yamaguchi, Yewdell, Yu   +67 more
core   +3 more sources

mRNA vaccine: a potential therapeutic strategy

Molecular Cancer, 2021
mRNA vaccines have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production.
Yang Wang, Ziqi Zhang, Jingwen Luo, Xuejiao Han, Yuquan Wei, Xiawei Wei   +5 more
doaj   +1 more source

mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients

Vaccines, 2021
Malignant melanoma is one of the most aggressive forms of cancer and the leading cause of death from skin tumors. Given the increased incidence of melanoma diagnoses in recent years, it is essential to develop effective treatments to control this disease.
Maryam Bidram, Yue Zhao, Natalia G. Shebardina, Alexey V. Baldin, Alexandr V. Bazhin, Mohamad Reza Ganjalikhany, Andrey A. Zamyatnin, Mazdak Ganjalikhani-hakemi   +7 more
doaj   +1 more source

Excipients and mRNA vaccines

Journal of Excipients and Food Chemicals, 2020
None
Shireesh Apte
doaj  

Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice [PDF]

, 2019
Background: Current human influenza vaccines lack the adaptability to match the mutational rate of the virus and therefore require annual revisions. Because of extensive manufacturing times and the possibility that antigenic alterations occur during ...
Aerts, Joeri, Christopoulou, Ioanna, Heirman, Carlo, Joe, Patrick Tjok, Saelens, Xavier, Schepens, Bert, Thielemans, Kris, Van Hoecke, Lien, Ysenbaert, Tine   +8 more
core   +2 more sources